Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond. A look at the numbers
Publishing timestamp: 2023-10-23 17:42:02
Summary
The article discusses the potential market size for weight loss drugs such as Wegovy and Mounjaro. Estimates vary, with Citi raising its estimate to $71 billion by 2035 and Guggenheim predicting a $150 billion to $200 billion opportunity. Analysts believe that GLP-1-based incretins will become the most prescribed drugs ever. However, there are challenges such as high drug prices and limited insurance coverage. Despite these challenges, analysts expect the market to reach around $100 billion by 2030, with Eli Lilly and Novo Nordisk expected to dominate the market. Both companies' stocks have seen significant gains.
Sentiment: NEUTRAL
Keywords: health care industry, novo nordisk a/s, eli lilly and co, breaking news: investing, investment strategy, business news,